Innovative Science Affordable Medicine


Wellmarker Bio and Cytogen Teams Up for Companion Diagnostics

2019-06-17 10:58

Wellmarker Bio and Cytogen Teams Up for Companion Diagnostics

싸이토젠 사진

Wellmarker Bio signed a Cooperative Research and Development Agreement (CRADA) with Cytogen, a company specialized in liquid biopsy based on Circulating Tumor Cell (CTC), on June 13, 2019. Through the joint research on companion diagnostics technology, Wellmarker Bio hopes to boost its drug development speed and improve its efficiency by accurately predicting the response and mechanisms of novel drugs through the CTC based liquid biopsy technology.

Companion diagnostics is a test that could predict the patient’s therapeutic response to certain anticancer drugs via in vitro assay, helping to determine safe and effective drugs for the patient. With an increasing demand for precision medicine and reduced cost of drug development, the global market is growing at around 18% year by year.

“Through collaborative R&D with Wellmarker Bio, we once again checked out the excellence of the CTC-based liquid biopsy technology in biomarker development and efficacy test. At the same time, we are able to step closer to the companion diagnostics market, which is worth USD 5.8billion.” said one of the representatives from Cytogen.